BACKGROUND: Both depression and cognitive impairment are common in hemodialysis patients, are associated with adverse clinical outcomes, and place an increased burden on health care resources. STUDY DESIGN: Cross-sectional cohort. SETTING & PARTICIPANTS: 241 maintenance hemodialysis patients in the Boston, MA, area. PREDICTOR: Depressive symptoms, defined as a Center for Epidemiological Studies Depression Scale (CES-D) score ≥16. OUTCOME: Performance on a detailed neurocognitive battery. RESULTS: Mean age was 63.8 years, 49.0% were women, 21.6% were African American, and median dialysis therapy duration was 13.8 months. There were 57 (23.7%) participants with significant depressive symptoms. In multivariable analysis adjusting for age, sex, education, and other comorbid conditions, participants with and without depressive symptoms performed similarly on the Mini-Mental State Examination (P = 0.4) and tests of memory. However, participants with greater depressive symptoms performed significantly worse on tests assessing processing speed, attention, and executive function, including Trail Making Test B (P = 0.02) and Digit-Symbol Coding (P = 0.01). Defining depression using a CES-D score ≥18 did not substantially change results. LIMITATIONS: Cross-sectional design, absence of brain imaging. CONCLUSIONS: Hemodialysis patients with a greater burden of depressive symptoms perform worse on tests of cognition related to processing speed and executive function. Further research is needed to assess the effects of treating depressive symptoms on cognitive performance in dialysis patients.
BACKGROUND: Both depression and cognitive impairment are common in hemodialysis patients, are associated with adverse clinical outcomes, and place an increased burden on health care resources. STUDY DESIGN: Cross-sectional cohort. SETTING & PARTICIPANTS: 241 maintenance hemodialysis patients in the Boston, MA, area. PREDICTOR: Depressive symptoms, defined as a Center for Epidemiological Studies Depression Scale (CES-D) score ≥16. OUTCOME: Performance on a detailed neurocognitive battery. RESULTS: Mean age was 63.8 years, 49.0% were women, 21.6% were African American, and median dialysis therapy duration was 13.8 months. There were 57 (23.7%) participants with significant depressive symptoms. In multivariable analysis adjusting for age, sex, education, and other comorbid conditions, participants with and without depressive symptoms performed similarly on the Mini-Mental State Examination (P = 0.4) and tests of memory. However, participants with greater depressive symptoms performed significantly worse on tests assessing processing speed, attention, and executive function, including Trail Making Test B (P = 0.02) and Digit-Symbol Coding (P = 0.01). Defining depression using a CES-D score ≥18 did not substantially change results. LIMITATIONS: Cross-sectional design, absence of brain imaging. CONCLUSIONS: Hemodialysis patients with a greater burden of depressive symptoms perform worse on tests of cognition related to processing speed and executive function. Further research is needed to assess the effects of treating depressive symptoms on cognitive performance in dialysis patients.
Authors: George S Alexopoulos; Dimitris N Kiosses; Moonseong Heo; Christopher F Murphy; Bindu Shanmugham; Faith Gunning-Dixon Journal: Biol Psychiatry Date: 2005-08-01 Impact factor: 13.382
Authors: Michael A Rapp; Karen Dahlman; Mary Sano; Hillel T Grossman; Vahram Haroutunian; Jack M Gorman Journal: Am J Psychiatry Date: 2005-04 Impact factor: 18.112
Authors: A M Murray; D E Tupper; D S Knopman; D T Gilbertson; S L Pederson; S Li; G E Smith; A K Hochhalter; A J Collins; R L Kane Journal: Neurology Date: 2006-07-25 Impact factor: 9.910
Authors: Arema A Pereira; Daniel E Weiner; Tammy Scott; Priya Chandra; Robyn Bluestein; John Griffith; Mark J Sarnak Journal: Hemodial Int Date: 2007-07 Impact factor: 1.812
Authors: Manisha Jhamb; Manjula K Tamura; Jennifer Gassman; Amit X Garg; Robert M Lindsay; Rita S Suri; George Ting; Fredric O Finkelstein; Scott Beach; Paul L Kimmel; Mark Unruh Journal: Blood Purif Date: 2011-01-10 Impact factor: 2.614
Authors: Eric P Sorensen; Mark J Sarnak; Hocine Tighiouart; Tammy Scott; Lena M Giang; Bethany Kirkpatrick; Kristina Lou; Daniel E Weiner Journal: Am J Kidney Dis Date: 2012-03-15 Impact factor: 8.860
Authors: David A Drew; Hocine Tighiouart; Jasmine Rollins; Sarah Duncan; Seda Babroudi; Tammy Scott; Daniel E Weiner; Mark J Sarnak Journal: J Am Soc Nephrol Date: 2020-03-04 Impact factor: 10.121
Authors: Jerzy A Zoladz; Michał Śmigielski; Joanna Majerczak; Łukasz R Nowak; Justyna Zapart-Bukowska; Olgierd Smoleński; Jan Kulpa; Krzysztof Duda; Joanna Drzewińska; Grzegorz Bartosz Journal: Neurochem Res Date: 2012-08-19 Impact factor: 3.996
Authors: Li Fan; Mark J Sarnak; Hocine Tighiouart; David A Drew; Amy L Kantor; Kristina V Lou; Kamran Shaffi; Tammy M Scott; Daniel E Weiner Journal: Am J Nephrol Date: 2014-06-24 Impact factor: 3.754